15 completed, 6 recruiting, 4 active not recruiting, 3 terminated. 11 Phase 2, 10 Phase 3, 8 Phase 1, 1 Phase 4.
Follow pegcetacoplan: new trials by email Literature Review of pegcetacoplan trials Research Report on pegcetacoplan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients Pegcetacoplan - C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN), Recurrent Glomerular Disease After Kidney Transplantation | Phase 3 | Recruiting | Swedish Orphan Biovitrum | 30 | 2027-01-21 | 2026-11-09 |
| Safely Quenching Complement in Stroke Survivors Pegcetacoplan Injection [Empaveli] - Acute Ischemic Stroke, Cerebral Infarction | Phase 1 | Not yet recruiting | Columbia University | 20 | 2026-10-01 | 2026-04-29 |
| Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study Pegcetacoplan - C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | Phase 4 | Recruiting | Swedish Orphan Biovitrum | 150 | 2026-08-05 | 2026-09-09 |
| Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation Pegcetacoplan, Placebo - Delayed Graft Function, End Stage Renal Disease | Phase 3 | Withdrawn | Apellis Pharmaceuticals, Inc. | 2026-05-18 | 2026-09-02 | |
| Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Roswell Park Cancer Institute | 35 | 2026-02-16 | 2026-08-19 |
| Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe APL-2, Pegcetacoplan - Geographic Atrophy Secondary to Age-related Macular Degeneration | Phase 3 | Completed | Apellis Pharmaceuticals, Inc. | 44 | 2025-10-24 | 2025-12-17 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) RO7669330, Syfovre™, Izervay™ - Geographic Atrophy, Age-related Macular Degeneration | Phase 1 | Terminated | Hoffmann-La Roche | 27 | 2025-07-16 | 2026-11-04 |
| A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio APL-3007, pegcetacoplan (APL-2), Placebo, Syfovre - Geographic Atrophy Secondary to Age-related Macular Degeneration | Phase 2 | Recruiting | Apellis Pharmaceuticals, Inc. | 240 | 2025-06-23 | 2026-06-24 |
| A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy BI 771716, Pegcetacoplan, Sham comparator to BI 771716 - Macular Degeneration, Age-related, Geographic Atrophy | Phase 2 | Active not recruiting | Boehringer Ingelheim | 202 | 2025-01-06 | 2026-05-14 |
| A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Pegcetacoplan - Geographic Atrophy | Active not recruiting | Apellis Pharmaceuticals, Inc. | 300 | 2023-09-28 | 2026-06-01 | |
| A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Pegcetacoplan - Paroxysmal Nocturnal Hemoglobinuria | Active not recruiting | Swedish Orphan Biovitrum | 165 | 2023-06-26 | 2026-09-03 | |
| An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Pegcetacoplan - C3G, IC-MPGN | Phase 3 | Active not recruiting | Apellis Pharmaceuticals, Inc. | 100 | 2023-05-29 | 2026-04-02 |
| APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion Bevacizumab, Biopsy, Biospecimen Collection - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 60 | 2023-04-27 | 2026-03-23 |
| A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD) Pegcetacoplan, Placebo matching Pegcetacoplan - Cold Agglutinin Disease | Phase 3 | Completed | Swedish Orphan Biovitrum | 24 | 2022-10-20 | 2025-10-30 |
| A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation Pegcetacoplan - Transplant-Associated Thrombotic Microangiopathy | Phase 2 | Completed | Swedish Orphan Biovitrum | 12 | 2022-02-01 | 2025-11-28 |
| Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Pegcetacoplan, Placebo - C3G, IC-MPGN | Phase 3 | Completed | Apellis Pharmaceuticals, Inc. | 124 | 2021-11-12 | 2026-01-29 |
| Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Pegcetacoplan - C3G, IC-MPGN | Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 13 | 2021-09-07 | 2026-04-21 |
| An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD PEGCETACOPLAN (APL-2) - Geographic Atrophy Secondary to Age-related Macular Degeneration | Phase 3 | Completed | Apellis Pharmaceuticals, Inc. | 792 | 2021-03-04 | 2026-10-28 |
| A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Pegcetacoplan - Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria | Phase 2 | Recruiting | Apellis Pharmaceuticals, Inc. | 12 | 2021-02-04 | 2026-06-26 |
| MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) Pegcetacoplan (APL-2), Placebo - Amyotrophic Lateral Sclerosis, Motor Neuron Disease | Phase 2 | Terminated | Apellis Pharmaceuticals, Inc. | 249 | 2020-09-30 | 2025-04-24 |
Showing 20 of 31. Sign in to see all of them.
Geographic Atrophy (7) · Hemoglobinuria, Paroxysmal (6) · Glomerulonephritis, Membranoproliferative (4) · Anemia (3) · Hematologic Diseases (3) · Hemoglobinuria (3) · Hemolysis (3) · Macular Degeneration (3) · Amyotrophic Lateral Sclerosis (1) · Anemia, Hemolytic (1) · Anemia, Hemolytic, Autoimmune (1) · Cerebral Infarction (1) · Delayed Graft Function (1) · Fallopian Tube Neoplasms (1) · Glomerulonephritis (1)
Apellis Pharmaceuticals, Inc. (21) · Swedish Orphan Biovitrum (5) · Roswell Park Cancer Institute (2) · Boehringer Ingelheim (1) · Columbia University (1) · Hoffmann-La Roche (1)
United States (23) · Spain (14) · France (13) · United Kingdom (13) · Australia (12) · Italy (11) · Germany (10) · Canada (9) · Belgium (8) · Czechia (8) · Netherlands (8) · Brazil (7) · Japan (6) · Poland (5) · South Korea (5)
Federico Grossi, MD, PhD (4) · Federico Grossi, MD PhD (2) · Christos Fountzilas (1) · E Sander Connolly, MD (1) · Emese Zsiros (1)
PMID 35869170, PMID 37314061, PMID 37707673, PMID 39079163, PMID 40720060, PMID 42133432, PMID 33730455, PMID 34445916, PMID 35113137, PMID 35796199, PMID 35860926, PMID 35869984, PMID 35948209, PMID 36055332, PMID 36284220, PMID 37715860, PMID 37865470, PMID 38315872, PMID 38573482, PMID 38593241, PMID 38722644, PMID 38727860, PMID 38752918, PMID 38814626, PMID 39522752, PMID 40280279, PMID 40285403, PMID 40388106, PMID 41337715, PMID 41533918
2023 (2), 2025 (1), R01CA267690 (1)